FDA approves Retatrutide this year?

The prediction market consensus for "FDA approves Retatrutide this year?" stands at 15.0%.

YES contracts trade at 15.0¢, while NO contracts trade at 84.0¢.

With low liquidity and $829 in volume, pricing reflects active market participation.

Resolution Criteria

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

Market Interpretation

Prediction markets function as real-time consensus engines.

Traders continuously buy and sell outcome shares based on:

• breaking news
• macro developments
• public narratives
• institutional positioning
• probability reassessments

As a result, market pricing reflects aggregate trader expectations rather than static forecasts or polling systems.

At the current pricing structure:

• YES trades near 15.0¢
• NO trades near 84.0¢
• Implied probability sits near 15.0%

These probabilities may shift rapidly as new information enters the market.

Liquidity & Conviction Analysis

As of May 13, 2026 at 04:29 PM, liquidity conditions act as a primary structural filter on prediction market signal quality.

Medium liquidity conviction suggests moderate participation depth, where price discovery is active but not fully saturated by institutional or high-frequency flow.

Higher liquidity environments typically produce:

• tighter spreads
• faster price discovery
• stronger informational efficiency
• lower pricing instability

Lower liquidity environments tend to exhibit:

• wider spreads
• delayed consensus formation
• increased volatility from isolated trades
• weaker signal reliability in short time windows

Overall, liquidity acts as a direct proxy for how “stable” the implied probability surface is at any given moment.

Why This Signal Exists in Prediction Markets

Prediction markets function as continuous consensus engines where probability is not stated — it is priced.

Each trade updates a live belief distribution, turning scattered human judgment into a single evolving likelihood curve.

Compared to static polling or narrative reporting, this structure adapts instantly to:

• regime shifts in geopolitics
• macroeconomic shocks and policy changes
• institutional order flow and positioning
• narrative acceleration or decay
• liquidity-driven sentiment swings
• information asymmetry correction

In practice, these markets behave less like betting tools and more like real-time probabilistic sensors for world events.

They compress collective intelligence into a dynamic signal that updates with every transaction.

Market Structure Transition

As of May 13, 2026 at 04:29 PM, prediction markets have evolved into persistent global probability infrastructure.

Polymarket and Kalshi now operate as high-throughput probability engines, with cumulative volumes exceeding $150B+ and sustained monthly flow above $7B.

Market activity has shifted from episodic speculation toward continuous liquidity formation, where geopolitical events, macroeconomic narratives, elections, AI milestones, and financial expectations are constantly repriced in real time.

This transformation has turned prediction markets into always-on consensus surfaces capable of reflecting crowd intelligence faster than traditional media, polling systems, or institutional forecasting pipelines.